Corteva, Inc.

Report azionario NYSE:CTVA

Capitalizzazione di mercato: US$51.3b

Corteva Performance degli utili passati

Criteri Il passato verificati 0/6

Gli utili di Corteva sono diminuiti a un tasso medio annuo di -8.1%, mentre il settore Chemicals ha visto gli utili diminuire a un tasso medio annuo di 2.9%. I ricavi sono cresciuti crescere a un tasso medio annuo di 2.1%. Il ritorno sul capitale proprio di Corteva è 4.3% e ha margini netti di 6.1%.

Informazioni chiave

-8.14%

Tasso di crescita degli utili

-5.94%

Tasso di crescita dell'EPS

Chemicals Crescita del settore12.93%
Tasso di crescita dei ricavi2.15%
Rendimento del capitale proprio4.32%
Margine netto6.09%
Ultimo aggiornamento sugli utili30 Jun 2026

Aggiornamenti sulle prestazioni recenti

Articolo di analisi May 14

Corteva's (NYSE:CTVA) Performance Is Even Better Than Its Earnings Suggest

Even though Corteva, Inc.'s ( NYSE:CTVA ) recent earnings release was robust, the market didn't seem to notice...

Recent updates

Aggiornamento narrativa Aug 04

CTVA: Upcoming Seed Spinoff And Crop Protection Pipeline Will Reshape Earnings Mix

Analysts lifted their price target for Corteva to $92.40 from $90.05, pointing to updated expectations around the Vylor seed spinoff, the crop protection and fertilizer backdrop, and the revised P/E and profitability assumptions cited in recent research. Analyst Commentary Recent research on Corteva centers on how the Vylor seed spinoff, crop protection trends, and fertilizer market conditions may affect valuation, growth prospects, and execution risk.
Seeking Alpha Jul 31

Corteva: Strong Fundamentals, Limited Upside

Summary Corteva, Inc. stands as a global leader in pure agri-tech, emphasizing R&D for advanced seed genetics and sustainable crop solutions. My prior Hold ratings on CTVA underestimated the market's preference for quality, execution, and improved business visibility over strict valuation metrics. CTVA has significantly outperformed the broader market by four times and its ETF peers by more than two times since my earlier reviews. The investment thesis now centers on CTVA's superior execution and enhanced operational visibility as key drivers of its recent outperformance. Read the full article on Seeking Alpha
Articolo di analisi Jun 20

Corteva (CTVA) Stock Could Be 13% Undervalued After FMC Herbicide Deal

Why the new FMC partnership matters for Corteva stock Corteva (CTVA) recently signed a multi-year, co-exclusive supply and license agreement with FMC Corporation for rimisoxafen herbicide technology, giving the company another tool in corn and soybean crop protection. The deal covers North and South American markets, includes a US$200 million prepurchase payment from Corteva, and allows both companies to create their own premix formulations. Commercial sales are targeted by the end of the...
Aggiornamento narrativa Jun 14

CTVA: Upcoming Spin Focused On Seed And Crop Protection Will Reshape Earnings Mix

Corteva's updated analyst price target edges higher by about $0.14 to roughly $90.05, as analysts refine their assumptions around revenue growth, profit margins and future P/E in light of recent target increases across the Street for the upcoming spin focused on seed and crop protection businesses. Analyst Commentary Recent research updates around Corteva cluster around the upcoming spin of its seed and crop protection businesses, with a series of higher price targets reflecting refreshed views on growth, execution and valuation for what some refer to as "New Corteva." Bullish analysts point to recalibrated assumptions on revenue, margins and P/E, while more cautious voices focus on whether the standalone company can consistently deliver against those expectations once separated.
Aggiornamento narrativa May 31

CTVA: SpinCo Separation And Biofungicide Collaboration Will Reshape Future Earnings Mix

The analyst price target for Corteva is updated to $89.90 from $86.05 as analysts note that the market is treating "New Corteva" like a no-growth commodity chemical company. They instead highlight expectations for a healthier standalone growth profile, modestly higher profit margins, and a slightly lower assumed future P/E multiple.
Articolo di analisi May 14

Corteva's (NYSE:CTVA) Performance Is Even Better Than Its Earnings Suggest

Even though Corteva, Inc.'s ( NYSE:CTVA ) recent earnings release was robust, the market didn't seem to notice...
Aggiornamento narrativa Apr 27

CTVA: Fair Value View Weighs Crop Protection Uncertainty And Planned SpinCo Separation

Corteva's analyst price target has increased by about $2, as analysts cite updated earnings models, a revised fair value of $86.05, a slightly adjusted discount rate, and modest changes to revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Street research on Corteva has been active, with several price target revisions and a mix of ratings changes that give you both supportive and cautious signals to weigh.
Aggiornamento narrativa Apr 13

CTVA: Fair Value View Balances Crop Protection Risks And Upcoming SpinCo Separation

The analyst price target for Corteva has moved modestly higher to align with a fair value estimate of about $84, as analysts factor in updated earnings models, slightly adjusted revenue growth and profit margin assumptions, and recent price target changes across several firms. Analyst Commentary Recent Street research on Corteva shows a mix of higher price targets and a few rating downgrades, so you are seeing both optimism and caution reflected in the current analyst debate.
Aggiornamento narrativa Mar 28

CTVA: Crop Protection Uncertainty And SpinCo Separation Will Shape Future Risk Balance

The analyst price target for Corteva has been nudged higher, with a modest fair value uplift to $83.95 as analysts balance a series of recent target increases from multiple firms against more cautious views tied to softer crop protection trends. Analyst Commentary Recent research on Corteva reflects a split view, with several firms lifting price targets while others turn more cautious on near term fundamentals, especially in crop protection.
Aggiornamento narrativa Mar 12

CTVA: Mixed Crop Protection Outlook And New SpinCo Plan Will Shape Risk Balance

The analyst price target for Corteva edges higher to $83.33 from $82.76, as analysts factor in slightly firmer long term revenue growth and profit margins, while balancing more cautious views on crop protection trends and a modestly lower discount rate. Analyst Commentary Recent research on Corteva reflects a split view, with several firms lifting price targets while others turn more cautious on execution in crop protection.
Aggiornamento narrativa Feb 26

CTVA: Sector Uncertainty And New Ventures Will Shape Forward Risk Balance

Corteva's analyst fair value estimate has edged up to $82.76 from $82.05 as analysts refine their models and price targets following recent earnings updates and a broad wave of upward target revisions across the Street. Analyst Commentary Recent Street research around Corteva reflects an active debate, with several firms adjusting price targets and a mix of upgrades and downgrades around the latest earnings update.
Aggiornamento narrativa Feb 11

CTVA: Mixed Sector Backdrop And New Ventures Will Shape Future Prospects

Corteva's analyst fair value estimate has increased to $82.05 from $78.43 as analysts factor in slightly stronger revenue growth assumptions, a higher future P/E multiple, and a modestly lower discount rate, even as projected profit margins are trimmed. Analyst Commentary Recent Street research on Corteva is mixed, with several bullish analysts lifting price targets while a few high profile firms turn more cautious.
Aggiornamento narrativa Jan 26

CTVA: Seed And Crop Protection Split Will Shape Balanced Future Prospects

Narrative Update Analysts have modestly raised their price expectations for Corteva, with the updated fair value estimate moving by about US$0.48 per share. This reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E, and is supported by recent target increases from several firms.
Aggiornamento narrativa Jan 11

CTVA: Planned Seed And Pesticide Split Will Support Future Earnings Power

Analysts lifted their blended fair value estimate for Corteva by about $0.19 to roughly $77.95 per share, reflecting updated price targets that factor in a mixed backdrop for chemicals and agriculture but continued confidence in the company’s ability to increase earnings. Analyst Commentary Recent research on Corteva reflects a mix of optimism and caution, with price targets clustered in the mid to high US$70s and one outlier in the low US$80s.
Aggiornamento narrativa Dec 18

CTVA: Planned Seed And Pesticide Split Will Unlock Future Earnings Power

The analyst price target for Corteva has been nudged higher by approximately $0.05 to about $77.76, as analysts factor in a slightly lower discount rate and modestly improved long term growth expectations, despite broadly cautious sector commentary and recent target reductions. Analyst Commentary Street research on Corteva reflects a divided but generally constructive view, with price targets drifting lower but ratings remaining skewed toward positive as investors reassess the company’s post breakup trajectory and near term earnings backdrop.
Aggiornamento narrativa Dec 03

CTVA: Planned Seed And Pesticide Split Will Unlock Future Earnings Power

Our analyst price target for Corteva has been trimmed modestly in line with recent Street moves, as analysts factor in lower sector multiples and near term earnings uncertainty around the planned split, while still recognizing the company’s intact innovation engine and long term earnings growth potential. Analyst Commentary Street views on Corteva have become more bifurcated following the announced split, with valuation targets reset lower but ratings broadly supportive of the long term strategic rationale and earnings power.
Articolo di analisi Nov 26

A Look At The Fair Value Of Corteva, Inc. (NYSE:CTVA)

Key Insights Corteva's estimated fair value is US$63.85 based on 2 Stage Free Cash Flow to Equity Current share price...
Aggiornamento narrativa Nov 19

CTVA: Upcoming Seed And Pesticide Split Will Unlock Shareholder Value

The analyst consensus price target for Corteva has been modestly reduced, slipping from approximately $77.86 to $77.71. Analysts reflect more cautious expectations for earnings growth in light of a mixed agricultural outlook and anticipated impacts from the company's planned business split.
Aggiornamento narrativa Nov 05

CTVA: Share Split Will Drive Shareholder Value Unlocking Amid Ongoing Business Realignment

Analysts have modestly reduced their average price target for Corteva by approximately $1.20. They cite a more cautious outlook amid challenging crop protection conditions and the company's recent announcement to split into two separate businesses.
Aggiornamento narrativa Oct 22

Analysts Offer Mixed Views as Corteva Eyes Split and Updates Guidance Amid Modest Valuation Shift

Analysts have modestly reduced their price target for Corteva by about $0.76 to $79.05. They cite uncertainty regarding the company’s planned split and the retention of legacy liabilities, though fundamentals and growth remain largely stable.
Aggiornamento narrativa Oct 08

High-Yield Seed Demand And Eco Policies Will Transform Agriculture

Corteva's analyst price target has been modestly reduced by $0.95 per share. Analysts cite continued uncertainty around the planned corporate split and complex crop protection market dynamics.
Aggiornamento narrativa Sep 04

High-Yield Seed Demand And Eco Policies Will Transform Agriculture

Analysts maintained their price target for Corteva at $80.76, citing margin expansion and EBITDA growth driven by successful innovation, favorable market fundamentals, and strong execution. Analyst Commentary Ongoing cost reductions, successful innovation, and strong execution are driving margin expansion and double-digit EBITDA growth.
Articolo di analisi Aug 26

Corteva's (NYSE:CTVA) Shareholders Will Receive A Bigger Dividend Than Last Year

Corteva, Inc. ( NYSE:CTVA ) will increase its dividend from last year's comparable payment on the 15th of September to...
Seeking Alpha Apr 21

Corteva: Upgraded To Strong Buy On Tariffs, Currency Tailwinds, Strong Guidance

Summary Upgrading Corteva from Buy to Strong Buy due to macro conditions, including tariff-induced supply shocks, rising commodity prices, and currency tailwinds. Corteva's diversified supply chain and local production in seeds position it to benefit from regionalization and potential inflationary pressures in the agricultural sector. Strong Q4 earnings, record operating EBITDA margin, and robust free cash flow support the bullish outlook, with significant shareholder returns through dividends and buybacks. Improved valuation at 20x forward earnings, solid balance sheet, and technical indicators suggest potential for further upside in the current market environment. Read the full article on Seeking Alpha
Seeking Alpha Mar 30

Pure Market Inefficiency In Corteva Preferreds Pricings

Summary This article explores a market inefficiency in fixed-income securities, specifically between Corteva's $4.50 and $3.50 Series Cumulative Preferred Stocks. We identified an arbitrage opportunity due to technical buying, making it an ideal pair trade with identical issues from the same company. On 02/09/2025, we recommended CTA-B for our investment-grade long-duration portfolio. On 02/10/2025, technical high-volume buying in CTA-A turned our initial investment idea into a pair trade. This pair trade highlights how technical factors can create profitable opportunities in fixed-income securities, especially among identical issues from the same issuer. Read the full article on Seeking Alpha

Ripartizione dei ricavi e delle spese

Come Corteva guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storico di utili e ricavi

NYSE:CTVA Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&S
30 Jun 2617,8121,0853,6231,493
31 Mar 2617,8891,2523,6281,480
31 Dec 2517,4011,1933,5151,474
30 Sep 2517,4691,6813,4201,426
30 Jun 2517,1771,4693,3971,423
31 Mar 2516,8331,1423,3251,405
31 Dec 2416,9088513,3401,402
30 Sep 2416,6376703,3331,394
30 Jun 2416,9018743,3251,381
31 Mar 2416,8346983,3181,353
31 Dec 2317,2269293,2951,337
30 Sep 2317,3441,1193,3031,320
30 Jun 2317,5311,1123,2381,297
31 Mar 2317,7381,2343,0991,264
31 Dec 2217,4551,2053,0101,216
30 Sep 2217,1091,4012,7061,192
30 Jun 2216,7031,7602,4171,177
31 Mar 2216,0781,7762,1431,174
31 Dec 2115,6551,8121,8911,187
30 Sep 2115,3831,7562,0551,176
30 Jun 2114,8751,3302,2131,163
31 Mar 2114,4391,0752,4171,143
31 Dec 2014,2177362,6751,142
30 Sep 2013,9935942,7441,127
30 Jun 2014,0414702,8391,132
31 Mar 2014,4061792,8561,128
31 Dec 1913,846-2882,8741,147
30 Sep 1913,678-1,3222,7971,202
30 Jun 1913,714-6,4532,7641,238
31 Mar 1912,921-6,9652,6621,312
31 Dec 1814,287-6,8132,7661,355
30 Sep 1814,299-3,5382,7861,393
30 Jun 1814,2201,2612,8881,455
31 Mar 1814,2301,8982,9301,482
31 Dec 1710,6842,0813,0821,075
31 Dec 1614,0415032,9371,507

Guadagni di qualità: CTVA ha un grande una tantum perdita di $1.1B che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 30th June, 2026.

Margine di profitto in crescita: Gli attuali margini di profitto netti di CTVA (6.1%) sono inferiori rispetto allo scorso anno (8.6%).


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di CTVA sono diminuiti del 8.1% all'anno negli ultimi 5 anni.

Accelerare la crescita: CTVA ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.

Guadagni vs Settore: CTVA ha avuto una crescita negativa degli utili ( -26.1% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Chemicals ( -2.4% ).


Rendimento del capitale proprio

ROE elevato: Il Return on Equity ( 4.3% ) di CTVA è considerato basso.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/10 04:19
Prezzo dell'azione a fine giornata2026/08/10 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Corteva, Inc. è coperta da 34 analisti. 19 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
null nullArgus Research Company
Benjamin TheurerBarclays
Aron CeccarelliBerenberg